Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on the Effect of Tinzaparin Sodium on Survival in Patients with Advanced Pancreatic Cancer

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment called tinzaparin sodium on patients with advanced pancreatic cancer. Pancreatic cancer is a serious condition where cancer cells form in the tissues of the pancreas, an organ that helps with digestion and blood sugar regulation. The treatment being tested is a type of medication known as a low molecular weight heparin, which is used to prevent blood clots. The study aims to see if using tinzaparin sodium can help improve the time patients live without their cancer getting worse, known as progression-free survival.

Participants in the study will receive tinzaparin sodium through injections. The study will compare the outcomes of patients receiving this treatment with those who do not, to understand its effectiveness in preventing blood clots during cancer treatment. The study will also monitor any side effects, such as bleeding, and assess the overall survival of patients receiving the treatment. The goal is to determine if tinzaparin sodium can be a beneficial addition to the standard chemotherapy regimen for pancreatic cancer.

The study will take place over a period of time, with regular check-ups to monitor the health and progress of the participants. The results will help researchers understand if tinzaparin sodium can improve the quality of life and survival rates for patients with advanced pancreatic cancer. This research is important for developing better treatment strategies for this challenging disease.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after meeting specific criteria, including a confirmed diagnosis of locally advanced or metastatic pancreatic cancer, being 18 years or older, and planning to start first-line chemotherapy with NabG.

    A written informed consent is required to proceed.

  2. Step 2

    Treatment initiation

    The study involves the administration of tinzaparin sodium, a medication used to prevent blood clots.

    The medication is provided as a solution for injection in pre-filled syringes, administered subcutaneously (under the skin).

    The dosage options include 10,000 anti Xa IU/0.5mL, 18,000 anti Xa IU/0.9mL, and 14,000 anti Xa IU/0.7mL, depending on the specific requirements of the treatment plan.

  3. Step 3

    Ongoing treatment and monitoring

    The primary goal is to evaluate the impact of preventing venous thromboembolism (VTE) on progression-free survival.

    The study also investigates the effectiveness of long-term VTE prevention while receiving chemotherapy.

    Regular monitoring for any VTE events, including deep vein thrombosis or pulmonary embolism, is conducted.

  4. Step 4

    Evaluation of outcomes

    The primary outcomes include progression-free survival and the occurrence of VTE events.

    Secondary outcomes involve the percentage of patients experiencing bleeding events, overall response rate, quality of life changes, and overall survival.

    The study is expected to conclude by August 2025.

Who can join the trial?

6 criteria

  • The patient must have **locally advanced** or **metastatic pancreatic cancer**. This means the cancer is either in the pancreas and nearby areas or has spread to other parts of the body. This must be confirmed by recommended tests.
  • The patient must be **18 years or older**.
  • The patient should be planning to start **1st line chemotherapy** with a drug called **NabG**. This is the first treatment given for cancer.
  • The patient must have an **ECOG score** of 0-2. This is a scale used to assess how well a patient can perform daily activities. A score of 0 means fully active, while 2 means the patient is up and about more than half the day.
  • The patient should have a **life expectancy of more than 6 months**.
  • The patient must provide **written informed consent**. This means they agree to participate in the study after being fully informed about it.

Who cannot join the trial?

6 criteria

  • Patients who are not receiving treatment for advanced pancreatic cancer.
  • Patients who are not undergoing chemotherapy with NabG.
  • Patients who are not eligible for VTE prevention. VTE stands for venous thromboembolism, which is a condition where blood clots form in the veins.
  • Patients who are not able to receive the medication tinzaparin. Tinzaparin is a type of medication used to prevent blood clots.
  • Patients who are not in the age range specified for the study.
  • Patients who are part of a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Tinzaparin

    is a medication used in this study to prevent blood clots in patients with advanced pancreatic cancer. It is administered alongside chemotherapy to help reduce the risk of venous thromboembolism (VTE), which is a common complication in cancer patients. The study aims to see if using tinzaparin can improve the time patients live without their cancer getting worse.

  • Nab-Paclitaxel

    (NabG) is a form of chemotherapy used in the treatment of advanced pancreatic cancer. It works by stopping the growth of cancer cells and is used as a first-line treatment in this study. The goal is to evaluate its effectiveness when used together with tinzaparin in preventing cancer progression.

What is already known about the treatment

Tinzaparin – Tinzaparin is administered via subcutaneous injection and is currently being studied for its role in preventing blood clots in patients with advanced pancreatic cancer. It is a low molecular weight heparin, which is well-documented in medical literature for its anticoagulant properties. The main therapeutic indication for tinzaparin in this context is thromboprophylaxis, or the prevention of blood clots, particularly in patients undergoing chemotherapy. At the molecular level, tinzaparin works by inhibiting factor Xa and thrombin, which are crucial components in the blood clotting process. It is classified pharmacologically as an anticoagulant.

Investigated diseases

Pancreatic Cancer – Pancreatic cancer is a disease where malignant cells form in the tissues of the pancreas, an organ located behind the stomach. It often progresses silently, with symptoms appearing only in advanced stages. As the cancer grows, it can spread to nearby organs and tissues, such as the liver and lymph nodes. The disease can cause symptoms like jaundice, weight loss, and abdominal pain. In advanced stages, it may lead to complications such as blockages in the bile duct or intestines. The progression of pancreatic cancer can vary, but it typically advances quickly once symptoms become noticeable.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-520043-17-00Protocol codeimPaCT-PRO-01Estimated enrolment450 patientsSponsorInstitute Of Molecular Medicine And Biomedical Research

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).